Research programme: psychiatric and neurological disorders therapeutics - Neuronascent

Drug Profile

Research programme: psychiatric and neurological disorders therapeutics - Neuronascent

Alternative Names: NNI-351

Latest Information Update: 03 Feb 2017

Price : $50

At a glance

  • Originator Neuronascent
  • Class Small molecules
  • Mechanism of Action DYRK kinase inhibitors; Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Down syndrome; Major depressive disorder; Post-traumatic stress disorders

Most Recent Events

  • 24 Jan 2017 Preclinical development for Down syndrome, Post-traumatic stress disorder and Major depressive disorder is ongoing in USA
  • 24 Jan 2017 Neuronascent has patent protection for several new groups of compounds treating neurological conditions in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Down syndrome in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top